Last reviewed · How we verify
ESW group
ESW group refers to extracorporeal shock wave therapy, a non-invasive mechanical treatment that uses acoustic energy pulses to stimulate tissue healing and regeneration.
ESW group refers to extracorporeal shock wave therapy, a non-invasive mechanical treatment that uses acoustic energy pulses to stimulate tissue healing and regeneration. Used for Chronic kidney disease, Renal ischemia-reperfusion injury.
At a glance
| Generic name | ESW group |
|---|---|
| Also known as | STEROID AVOIDANCE, STEROID WITHDRAWAL |
| Sponsor | Unidad de Investigacion Medica en Enfermedades Renales |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Mechanism of action
Extracorporeal shock waves generate mechanical stress that triggers cellular responses including neovascularization, growth factor release, and tissue remodeling. This mechanism is thought to promote healing in damaged tissues, particularly in renal and musculoskeletal conditions, by activating endogenous repair pathways and improving blood flow to affected areas.
Approved indications
- Chronic kidney disease
- Renal ischemia-reperfusion injury
Common side effects
- Pain at treatment site
- Transient hematuria
- Skin erythema
Key clinical trials
- RCT How an Online Escape Room Game Enhances Nurses' Learning Outcomes Regarding ESW Signs. (NA)
- Effect of Extracorporeal Shock Wave Combined With Autologous Platelet-rich Plasma Injection on Rotator Cuff Calcific Tendinitis (NA)
- Myofascial Points Treatment With Focused Extracorporeal Shock Waves (ESW) (NA)
- Shear Wave Elastography Technology to Evaluate the Efficacy of ESW in the Treatment of Patients With Chronic Plantar Fasciitis (NA)
- Focused Shockwave Treatment in the Recovery Process of Acute Muscle Injuries in Soccer Players (NA)
- Validation of an Intermittent Shuttle Walking Protocol in Patients With COPD (NA)
- ESTEROID WITHDRAWAL STUDY, SAFETY AND EFFICACY IN RENAL TRANPLANTATION (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ESW group CI brief — competitive landscape report
- ESW group updates RSS · CI watch RSS
- Unidad de Investigacion Medica en Enfermedades Renales portfolio CI